Interim Report January - June 2001

Interim Report 1 January - 30 June 2001 · The company was floated on 12 June. The offer to acquire shares in conjunction with the listing was subscribed 2.5 times. The funds generated by the share issue amounted to SEK 261.6 million after issue costs. · New cooperation agreement for the supply of antibodies from n- CoDeR(TM) to Oxford GlycoSciences plc, a leading company within research into new targets for drug development. · Cooperation agreement with ImmunoGen Inc - an important breakthrough in the US market · Manufacturing agreement entered into in July with Igeneon AG · The accumulated cash flow from current operations and investments for the period was SEK -22.4 million (-17.6). Liquid funds for the period amounted to SEK 391.1 million · Net revenue increased to SEK 28.6 million (11.0) Lund, 6 August 2001 Svein Mathisen CEO I have briefly examined this interim report for the period 1 January 2001 - 30 June 2001 in accordance with the recommendations issued by the Swedish Institute of Authorised Public Accountants (FAR). A brief examination is very limited compared to a full audit. I have found nothing to indicate that this interim report does not meet the requirements of the stock exchange and annual accounts laws. Lund, 6 August 2001 ERNST & YOUNG AB Åke Stenmo Authorised Public Accountant Any questions regarding this report will be answered by Svein Mathisen, CEO, at +46 (0)46 286 85 67. Website: http://www.bioinvent.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00510/wkr0001.doc The full report http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00510/wkr0002.pdf The full report